Category Pharmaceuticals
CASGEVY: Rethinking Drug Costs Through the Lens of Public Access
Maria Klimenko considers the extent to which the price of innovative treatments like CASGEVY, a type of gene therapy, should reflect not just the cost of development, but also their broader societal impact — and the public healthcare system’s ability to provide equitable access.
Prove AI Can’t Care First
Jean-Christophe Bélisle-Pipon argues that defaulting to AI in health settings could do more harm than good.
Is Free, Canada-Wide Access to HIV Medications Reasonable?
Julian Hopwood-Raja argues that universal, barrier-free access to HIV medicines is not just a matter of beneficence for patients and the health system but important for public health and ethical resource allocation.
Let’s Raise the Bar for Research Ethics Standards on Psychedelics
Paola Cubillos draws attention to the ethical and methodological concerns from MDMA- Assisted Therapy research and argues that these issues merit a stringent research ethics oversight framework for psychedelic clinical studies.
The Moral Heritage of Bioethics East and West
Rashad Rehman argues that bioethicists should turn their attention to the shared moral heritage of both Western and non-Western bioethics.
Impact Ethics 